Revenue Recognition Segment revenue by major payor (Tables)

6 Months Ended

Jun. 30, 2024

Disaggregation of Revenue [Table Text Block]

The following tables summarize the Company's segment revenues by primary payor source:


	Three months ended June 30, 2024						Three months ended June 30, 2023
	U.S. dialysis		Other — Ancillary services		Consolidated		U.S. dialysis		Other — Ancillary services		Consolidated
Dialysis patient service revenues:
Medicare and Medicare Advantage	$	1,587,198	$		$	1,587,198	$	1,539,639	$		$	1,539,639
Medicaid and Managed Medicaid	214,951				214,951		216,014				216,014
Other government	80,338		176,524		256,862		92,525		125,964		218,489
Commercial	952,625		62,391		1,015,016		876,033		60,871		936,904
Other revenues:
Medicare and Medicare Advantage			97,433		97,433				87,236		87,236
Medicaid and Managed Medicaid			445		445				396		396
Commercial			10,200		10,200				3,619		3,619
Other(1)	5,898		15,467		21,365		6,404		13,437		19,841
Eliminations of intersegment revenues	(12,925)		(3,823)		(16,748)		(20,361)		(1,408)		(21,769)
Total	$	2,828,085	$	358,637	$	3,186,722	$	2,710,254	$	290,115	$	3,000,369


	Six months ended June 30, 2024						Six months ended June 30, 2023
	U.S. dialysis		Other - Ancillary services		Consolidated		U.S. dialysis		Other - Ancillary services		Consolidated
Dialysis patient service revenues:
Medicare and Medicare Advantage	$	3,118,696	$		$	3,118,696	$	3,022,405	$		$	3,022,405
Medicaid and Managed Medicaid	425,075				425,075		421,790				421,790
Other government	162,924		322,309		485,233		174,570		247,550		422,120
Commercial	1,878,455		132,564		2,011,019		1,711,427		115,387		1,826,814
Other revenues:
Medicare and Medicare Advantage			200,542		200,542				180,475		180,475
Medicaid and Managed Medicaid			841		841				965		965
Commercial			17,140		17,140				4,825		4,825
Other(1)	12,021		30,669		42,690		12,583		26,275		38,858
Eliminations of intersegment revenues	(37,389)		(6,570)		(43,959)		(42,410)		(2,774)		(45,184)
Total	$	5,559,782	$	697,495	$	6,257,277	$	5,300,365	$	572,703	$	5,873,068

(1) Consists primarily of management service fees in the Company's U.S. dialysis business and research fees, management fees, and other non-patient service revenues in the Other - ancillary services businesses.